Fwd: Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Apr 6, 2008 at 12:45 PM
Subject: Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer.
To: mesothelioma77@gmail.com


[1]Fam Cancer. 2008 Apr 4;
Myrhøj T, Andersen MB, Bernstein I

Aim The aim of this study was to evaluate if Urine Cytology (UC) is an appropriate screening procedure for detecting urinary tract neoplasia at an early stage in persons at risk in Hereditary Non-Polyposis Colorectal Cancer families. Method In the National Danish HNPCC-register persons at risk were identified in three categories of HNPCC-families (1) families harbouring a disease causing mutation in a Mismatch repair gene (MMR), (2) families fulfilling the Amsterdam I or II criteria and (3) families suspected of HNPCC. In total 3,411 persons were identified and traced in Patobank-the National Danish Pathology database. All UC and UTC (Urinary Tract Tumours) were listed and evaluated. Results 977 persons had a total of 1,868 screening procedures performed. Two of these procedures (0.1%) lead to diagnosis of an asymptomatic urothelial tumour. In ten times as many procedures (22 persons) UC lead to a false positive screening diagnosis. During the study period fourteen persons (1.4%) developed a UTC and five of these were interval tumours. The sensitivity of UC in diagnosing asymptomatic UTC in HNPCC patients was 29%. Twelve of the tumours were found in persons from families with a proven MMR-mutation and eleven out of these were MSH2 mutations (92%, 95% cl 62-100%). Discussion UC is not a proper method of screening for UTC in HNPCC. However, the study can not reveal if screening for UTC in special families ought to be recommended. Consequently, further studies needs to be performed in order to evaluate an appropriate screening programme.



___
Source: http://www.hubmed.org/display.cgi?uids=18389386
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Clinical Trials To Treat Lung Cancer (Malaysian National News Agency (BERNAMA))

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Apr 7, 2008 at 12:04 PM
Subject: Clinical Trials To Treat Lung Cancer (Malaysian National News Agency (BERNAMA))
To: mesothelioma77@gmail.com


KUALA LUMPUR, April 7 (Bernama) -- Soon, Cuba will not only be world famous for its cigars but also for a very promising vaccine meant to treat lung cancer and possibly other solid cancers.

Mon, 07 Apr 2008 11:17:45 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11t8ugo19/*http%3A//www.bernama.com/bernama/v3/news_lite.php?id=325209
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Listen to their answers! Response behaviour in the measurement of physical and role functioning.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Apr 6, 2008 at 12:45 PM
Subject: Listen to their answers! Response behaviour in the measurement of physical and role functioning.
To: mesothelioma77@gmail.com


[1]Qual Life Res. 2008 Apr 4;
Westerman MJ, Hak T, Sprangers MA, Groen HJ, van der Wal G, The AM

BACKGROUND: Quality of life (QoL) is considered to be an indispensable outcome measure of curative and palliative treatment. However, QoL research often yields findings that raise questions about what QoL measurement instruments actually assess and how the scores should be interpreted. OBJECTIVE: To investigate how patients interpret and respond to questions on the EORTC-QLQ-C30 over time and to find explanations to account for counterintuitive findings in QoL measurement. METHODS: Qualitative investigation was made of the response behaviour of small-cell lung cancer patients (n = 23) in the measurement of QoL with the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). Focus was on physical functioning (PF, items 1 to 5), role functioning (RF, items 6 and 7), global health and QoL rating (GH/QOL, items 29 and 30). Interviews were held at four points: at the start of the chemotherapy, 4 weeks later, at the end, and 6 weeks after the end of chemotherapy. Patients were asked to 'think aloud' when filling in the questionnaire. RESULTS: Patients used various response strategies when answering questions about problems and limitations in functioning, which impacted the accuracy of the scale. Patients had scores suggesting they were less limited than they actually were by taking the wording of questions literally, by guessing their functioning in activities that they did not perform, and by ignoring or excluding certain activities that they could not perform. CONCLUSION: Terminally ill patients evaluate their functioning in terms of what they perceive to be normal under the circumstances. Their answers can be interpreted in terms of change in the appraisal process (Rapkin and Schwartz 2004; Health and Quality of Life Outcomes, 2, 14). More care should be taken in assessing the quality of a set of questions about physical and role functioning.



___
Source: http://www.hubmed.org/display.cgi?uids=18389384
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc